- Home
- LOGC vs VTYX Comparison
LOGC vs VTYX Comparison
Compare LOGC & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOGC
- VTYX
- Stock Information
- Founded
- LOGC 2010
- VTYX 2018
- Country
- LOGC United States
- VTYX United States
- Employees
- LOGC N/A
- VTYX N/A
- Industry
- LOGC Catalog/Specialty Distribution
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- LOGC Consumer Discretionary
- VTYX Health Care
- Exchange
- LOGC Nasdaq
- VTYX Nasdaq
- Market Cap
- LOGC 186.6M
- VTYX 184.6M
- IPO Year
- LOGC 2020
- VTYX 2021
- Fundamental
- Price
- LOGC $6.74
- VTYX $2.30
- Analyst Decision
- LOGC
- VTYX Buy
- Analyst Count
- LOGC 0
- VTYX 5
- Target Price
- LOGC N/A
- VTYX $8.40
- AVG Volume (30 Days)
- LOGC 266.9K
- VTYX 2.3M
- Earning Date
- LOGC 11-07-2024
- VTYX 11-07-2024
- Dividend Yield
- LOGC N/A
- VTYX N/A
- EPS Growth
- LOGC N/A
- VTYX N/A
- EPS
- LOGC N/A
- VTYX N/A
- Revenue
- LOGC $96,000,000.00
- VTYX N/A
- Revenue This Year
- LOGC N/A
- VTYX N/A
- Revenue Next Year
- LOGC $422.91
- VTYX N/A
- P/E Ratio
- LOGC N/A
- VTYX N/A
- Revenue Growth
- LOGC N/A
- VTYX N/A
- 52 Week Low
- LOGC $4.01
- VTYX $1.67
- 52 Week High
- LOGC $8.24
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- LOGC 40.45
- VTYX 47.68
- Support Level
- LOGC $7.03
- VTYX $2.21
- Resistance Level
- LOGC $8.21
- VTYX $2.54
- Average True Range (ATR)
- LOGC 0.37
- VTYX 0.27
- MACD
- LOGC -0.16
- VTYX -0.05
- Stochastic Oscillator
- LOGC 12.98
- VTYX 8.02
About LOGC ContextLogic Inc.
ContextLogic Inc is an online shopping store. The store provides personalized products, clothing products, accessories, gaming products and equipment, cosmetics, plastic products, mobile covers, and other products. Geographically, it derives a majority of its revenue from Europe and also has a presence in North America; South America, and other countries.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.